Tyra Biosciences, Inc. (TYRA) 10-Year Financial Performance & Capital Metrics

TYRA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutTyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.Show more

Revenue $0
EBITDA -$104M -30.2%
Net Income -$86M -25.1%
EPS (Diluted) -1.51 +6.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -31.6% -5.6%
ROIC -38.1% +48.5%
Debt/Equity 0.02 -43.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 96 (top 4%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 34.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-33.37%

EPS CAGR

10Y-

5Y-

3Y-

TTM-16.15%

ROCE

10Y Avg-60.77%

5Y Avg-60.77%

3Y Avg-30.7%

Latest-37.24%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	8K	47K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-8K	-47K	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-4.88%	1%	-	-	-
Operating Expenses+	3.12M	9.25M	26.29M	58.93M	79.94M	104.18M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	1.33M	2.09M	5.65M	15.92M	17.43M	24.1M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	1.79M	7.2M	20.64M	43.01M	62.52M	80.08M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	-8K	-23K	0	0	0	0
Operating Income+	-3.12M	-9.3M	-26.29M	-58.93M	-79.94M	-104.18M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-1.98%	-1.83%	-1.24%	-0.36%	-0.3%
EBITDA+	-3.11M	-9.25M	-26.15M	-58.63M	-79.59M	-103.66M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-1.97%	-1.83%	-1.24%	-0.36%	-0.3%
D&A (Non-Cash Add-back)	8K	47K	140K	296K	357K	519K
EBIT	-3.12M	-9.34M	-26.29M	-58.93M	-79.94M	-104.18M
Net Interest Income+	-999	-999	13K	3.65M	10.81M	17.7M
Interest Income	0	0	13K	3.65M	10.81M	17.7M
Interest Expense	1K	1K	0	0	0	0
Other Income/Expense	-943K	-39K	-6K	3.6M	10.81M	17.7M
Pretax Income+	-4.07M	-9.34M	-26.29M	-55.33M	-69.13M	-86.48M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-4.06M	-9.31M	-26.29M	-55.33M	-69.13M	-86.48M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-1.3%	-1.82%	-1.1%	-0.25%	-0.25%
Net Income (Continuing)	-4.07M	-9.34M	-26.29M	-55.33M	-69.13M	-86.48M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.10	-0.22	-0.63	-1.23	-1.62	-1.51
EPS Growth %	-	-1.31%	-1.86%	-0.95%	-0.32%	0.07%
EPS (Basic)	-0.10	-0.22	-0.63	-1.23	-1.62	-1.51
Diluted Shares Outstanding	42.54M	42.54M	41.44M	41.88M	42.7M	57.22M
Basic Shares Outstanding	42.54M	42.54M	41.44M	41.88M	42.7M	57.22M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	127K	15.28M	304.06M	257.29M	211.67M	347.46M
Cash & Short-Term Investments	108K	15.22M	302.18M	251.21M	203.47M	341.44M
Cash Only	108K	15.22M	302.18M	251.21M	58.01M	91.97M
Short-Term Investments	0	0	0	0	145.46M	249.47M
Accounts Receivable	0	0	0	0	0	2M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	6.08M	8.2M	4.02M
Total Non-Current Assets+	401K	730K	2.64M	8.89M	14.19M	16.09M
Property, Plant & Equipment	276K	466K	2.09M	3.54M	8.15M	7.72M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	243K	0	0	0	0
Other Non-Current Assets	125K	21K	555K	5.35M	6.03M	8.38M
Total Assets+	528K	16.01M	306.7M	266.18M	225.86M	363.56M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	29.32%	18.16%	-0.13%	-0.15%	0.61%
Total Current Liabilities+	5.16M	1.86M	3.62M	5.7M	15.33M	14.59M
Accounts Payable	327K	664K	599K	1.15M	4.66M	590K
Days Payables Outstanding	14.92K	5.16K	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	4.33M	278K	0	0	5.27M	13.59M
Current Ratio	0.02x	8.22x	84.09x	45.13x	13.80x	23.81x
Quick Ratio	0.02x	8.22x	84.09x	45.13x	13.80x	23.81x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	114K	27.79M	1.35M	2.65M	6.26M	5.81M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	114K	0	981K	2.48M	6.22M	5.81M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	27.79M	367K	169K	46K	3K
Total Liabilities	5.27M	29.65M	4.96M	8.35M	21.59M	20.41M
Total Debt+	253K	142K	1.18M	2.62M	6.5M	6.22M
Net Debt	145K	-15.08M	-301M	-248.59M	-51.51M	-85.74M
Debt / Equity	-	-	0.00x	0.01x	0.03x	0.02x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-3122.00x	-9297.00x	-	-	-	-
Total Equity+	-4.74M	-13.64M	301.74M	257.83M	204.26M	343.15M
Equity Growth %	-	-1.88%	23.12%	-0.15%	-0.21%	0.68%
Book Value per Share	-0.11	-0.32	7.28	6.16	4.78	6.00
Total Shareholders' Equity	-4.74M	-13.64M	301.74M	257.83M	204.26M	343.15M
Common Stock	0	0	4K	4K	4K	5K
Retained Earnings	-4.74M	-14.08M	-40.37M	-95.7M	-164.83M	-251.31M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	381K	770K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.62M	-7.76M	-23.75M	-50.28M	-50.14M	-69.77M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-1.97%	-2.06%	-1.12%	0%	-0.39%
Net Income	-4.07M	-9.34M	-26.29M	-55.33M	-69.13M	-86.48M
Depreciation & Amortization	8K	47K	140K	296K	353K	519K
Stock-Based Compensation	0	439K	2.89M	0	0	22.8M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	934K	17K	3K	10.59M	12.28M	-5.88M
Working Capital Changes	505K	1.07M	-481K	-5.85M	6.36M	-729K
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	461K	1.02M	1.49M	0	0	0
Cash from Investing+	-20K	-312K	-645K	-559K	-144.6M	-98.4M
Capital Expenditures	-20K	-312K	-661K	-559K	-770K	-664K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	16	0	0	0
Cash from Financing+	157K	23.43M	311.35M	632K	1.54M	202.14M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	165K	140K	514K	0	0	2.56M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-2.64M	-8.07M	-24.41M	-50.84M	-50.91M	-70.44M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-2.06%	-2.02%	-1.08%	-0%	-0.38%
FCF per Share	-0.06	-0.19	-0.59	-1.21	-1.19	-1.23
FCF Conversion (FCF/Net Income)	0.65x	0.83x	0.90x	0.91x	0.73x	0.81x
Interest Paid	1K	1K	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-18.25%	-19.77%	-29.92%	-31.6%
Return on Invested Capital (ROIC)	-	-	-	-886.03%	-74.03%	-38.1%
Debt / Equity	-	-	0.00x	0.01x	0.03x	0.02x
Interest Coverage	-3122.00x	-9297.00x	-	-	-	-
FCF Conversion	0.65x	0.83x	0.90x	0.91x	0.73x	0.81x

Frequently Asked Questions

Growth & Financials

Tyra Biosciences, Inc. (TYRA) grew revenue by 0.0% over the past year. Growth has been modest.

Tyra Biosciences, Inc. (TYRA) reported a net loss of $111.7M for fiscal year 2024.

Dividend & Returns

Tyra Biosciences, Inc. (TYRA) has a return on equity (ROE) of -31.6%. Negative ROE indicates the company is unprofitable.

Tyra Biosciences, Inc. (TYRA) had negative free cash flow of $91.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener